Previous close | 6.60 |
Open | 6.17 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 125.00 |
Expiry date | 2024-05-10 |
Day's range | 5.80 - 7.05 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it plans to invest around $200 million in quantum computing startups. The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic. Experts believe quantum computing may prove to be among the most transformational technological developments of the 21st century.
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.